Relapsed Non-Hodgkin Lymphoma Clinical Trials

45 clinical trials for Relapsed Non-Hodgkin Lymphoma across international registries, including 15 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy — RECRUITING · PHASE3
• Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma — RECRUITING · PHASE1
• Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT — RECRUITING · PHASE1
• SynKIR-310 for Relapsed/Refractory B-NHL — RECRUITING · PHASE1
• Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL — RECRUITING · PHASE2
• CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Long-Term Follow-up Study — RECRUITING
• A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL — RECRUITING · PHASE2
• Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) — RECRUITING · PHASE1
• CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). — RECRUITING · PHASE2
• Emapalumab Prevention of CAR-T Cell Associated Toxicities — RECRUITING · PHASE2
• T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) — RECRUITING · PHASE1
• IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers — RECRUITING · PHASE1
• Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma — RECRUITING · PHASE2
• Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma — RECRUITING · PHASE1
• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies — TERMINATED · PHASE1
• CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) — ACTIVE_NOT_RECRUITING · PHASE1
• Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• CAR-T for R/R B-NHL — COMPLETED · PHASE2
• A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma — COMPLETED
• A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma — COMPLETED · PHASE2
• A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity — COMPLETED · PHASE2
• Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma — NOT_YET_RECRUITING · PHASE1
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) — OTHER · PHASE1
• Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma — OTHER · PHASE1
• A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome — TERMINATED · PHASE1
• First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma — NOT_YET_RECRUITING · PHASE1
• Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research — OTHER
• Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA) — NOT_YET_RECRUITING
• ThisCART19A for B-NHL Relapsed After Auto-CAR T — OTHER · PHASE1
• Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma — OTHER · PHASE2
• Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma — OTHER · PHASE1
• Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma — COMPLETED
• Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Intra-Osseous Co-Transplant of UCB and hMSC — COMPLETED · PHASE1
• Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma — TERMINATED · PHASE1
• MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin — OTHER · PHASE1
• Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT — COMPLETED
• Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL — COMPLETED · NA
• Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma — OTHER · PHASE1
• Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma — OTHER · PHASE2
• Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma — OTHER · PHASE1
• Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) — OTHER · PHASE1
• Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma — COMPLETED · PHASE2

Refine this search